Johnson Margaret O, Kirkpatrick John P, Patel Mallika P, Desjardins Annick, Randazzo Dina M, Friedman Henry S, Ashley David M, Peters Katherine B
Department of Neurosurgery, Duke University Hospital, Durham, NC 27710, USA.
Radiation Oncology, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA.
CNS Oncol. 2019 Nov 1;8(3):CNS41. doi: 10.2217/cns-2019-0012. Epub 2019 Nov 5.
Central neurocytoma (CN) is a rare WHO grade II central nervous system (CNS) tumor. This is an update on chemotherapeutic agents used in its treatment. An institutional review board-approved, chart review of patients seen at our institution resulted in a single case treated with chemotherapy and is herein included. We proceeded with a comprehensive literature review. We identified 18 citations, representing 39 cases of adult and pediatric CN treated with chemotherapy. With the addition of our single case, the total number of recurrent CN patients treated with temozolomide (TMZ) is nine. There exists marked heterogeneity in chemotherapy used to treat CN. TMZ is incorporated into treatment regimens in the setting of tumor recurrence: its role merits further study.
中枢神经细胞瘤（CN）是一种罕见的世界卫生组织（WHO）II级中枢神经系统（CNS）肿瘤。本文是关于其治疗中使用的化疗药物的最新情况。通过对我院机构审查委员会批准的病例记录进行回顾，发现仅有1例患者接受了化疗，本文将其纳入。我们还进行了全面的文献综述。我们共识别出18篇文献，涵盖39例接受化疗的成人和儿童CN病例。加上我们的这例病例，接受替莫唑胺（TMZ）治疗的复发性CN患者总数为9例。用于治疗CN的化疗方案存在显著异质性。TMZ已被纳入肿瘤复发情况下的治疗方案：其作用值得进一步研究。
